The British journal of dermatology · 2026
Efficacy and safety of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma in Japan: Results of the Japan Clinical Oncology Group single-arm confirmatory trial (JCOG1605).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oashi Kohei, Ogata Dai, Yokoyama Masayuki, Sano Yusuke, Fukuda Haruhiko, Hiura Azusa, Nakamura Yasuhiro, Uehara Jiro, Takahashi Akira, Namikawa Kenjiro, Mori Shoichiro, Nakano Eiji, Maeda Taku, Miyagawa Takuya, Yoshino Koji, Funakoshi Takeru, Kiniwa Yukiko, Nakagawa Tomoe, Shibayama Yoshitsugu, Uchi Hiroshi, Maeda Takuya, Muto Ikko, Maruyama Ayano, Takenouchi Tatsuya, Hatta Naohito, Yamazaki Naoya
Аннотация
BACKGROUND: Paclitaxel is a standard first-line chemotherapy for primary cutaneous angiosarcoma. However, there is no established second-line treatment after paclitaxel.
OBJECTIVES: The aim of the JCOG1605 study was to evaluate the efficacy and safety of second-line pazopanib for primary cutaneous angiosarcoma.
METHODS: This multi-institutional, single-arm, confirmatory trial was conducted in Japan. Patients with cutaneous angiosarcoma not associated with lymphedema or radiation exposure were included in this study. Pazopanib was administered orally at an initial dose of 800 mg, once daily. The primary endpoint was progression-free survival. Retrospective data on second-line docetaxel following first-line paclitaxel treatment were used as a historical control. This trial was registered in the UMIN Clinical Trials Registry (UMIN000031438 [http://www.umin.ac.jp/ctr/index.htm]).
RESULTS: Thirty patients were enrolled from 15 institutes and received pazopanib (n = 30). The median progression-free survival and overall survival were 2.8 months (80% CI: 2.1-3.9) and 12.1 months (95% CI: 8.9-28.8), respectively. The response and disease control rates were 31.8% (95% CI: 13.9-54.9) and 63.6% (95% CI: 40.7-82.8), respectively. Twenty-eight (93.3%) and 21 (70%) patients experienced grade ≥2 and grade ≥3 non-hematologic adverse events, respectively. No treatment-related deaths occurred.
CONCLUSIONS: The primary endpoint progression-free survival did not meet the predefined threshold. However, the response rate and overall survival were better than expected, and there were no safety issues. Therefore, pazopanib may be a treatment option for patients with paclitaxel-pretreated primary cutaneous angiosarcoma. (231/350 words).
OBJECTIVES: The aim of the JCOG1605 study was to evaluate the efficacy and safety of second-line pazopanib for primary cutaneous angiosarcoma.
METHODS: This multi-institutional, single-arm, confirmatory trial was conducted in Japan. Patients with cutaneous angiosarcoma not associated with lymphedema or radiation exposure were included in this study. Pazopanib was administered orally at an initial dose of 800 mg, once daily. The primary endpoint was progression-free survival. Retrospective data on second-line docetaxel following first-line paclitaxel treatment were used as a historical control. This trial was registered in the UMIN Clinical Trials Registry (UMIN000031438 [http://www.umin.ac.jp/ctr/index.htm]).
RESULTS: Thirty patients were enrolled from 15 institutes and received pazopanib (n = 30). The median progression-free survival and overall survival were 2.8 months (80% CI: 2.1-3.9) and 12.1 months (95% CI: 8.9-28.8), respectively. The response and disease control rates were 31.8% (95% CI: 13.9-54.9) and 63.6% (95% CI: 40.7-82.8), respectively. Twenty-eight (93.3%) and 21 (70%) patients experienced grade ≥2 and grade ≥3 non-hematologic adverse events, respectively. No treatment-related deaths occurred.
CONCLUSIONS: The primary endpoint progression-free survival did not meet the predefined threshold. However, the response rate and overall survival were better than expected, and there were no safety issues. Therefore, pazopanib may be a treatment option for patients with paclitaxel-pretreated primary cutaneous angiosarcoma. (231/350 words).